Hologic, Inc.
HOLX
주식 순위
#1326
Hologic, Inc. is a medical technology company focused on designing, producing,... Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
주가
$76.01
마지막 동기화: 2026-04-07
시가총액
$16.97B
변동 (1일)
0.00%
변동 (1년)
5.76%
국가
US
거래 Hologic, Inc. (HOLX)
카테고리
Healthcare
Hologic, Inc. (HOLX)의 P/E 비율
October 2026 기준 P/E 비율 TTM: 30.28
Hologic, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 30.28입니다. 2024년 말 기준 P/E 비율은 24.32였습니다.
Hologic, Inc.의 P/E 비율 기록 (2000 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 30.28 | 12.20% |
| 2025 | 26.99 | 10.98% |
| 2024 | 24.32 | -35.24% |
| 2023 | 37.56 | 208.68% |
| 2022 | 12.17 | 15.83% |
| 2021 | 10.50 | -30.71% |
| 2020 | 15.16 | -104.56% |
| 2019 | -332.48 | 228.24% |
| 2018 | -101.29 | -845.41% |
| 2017 | 13.59 | -58.28% |
| 2016 | 32.57 | -61.81% |
| 2015 | 85.28 | -78.02% |
| 2014 | 387.93 | -8,197.69% |
| 2013 | -4.79 | -93.36% |
| 2012 | -72.18 | -378.49% |
| 2011 | 25.92 | -137.77% |
| 2010 | -68.63 | 3,475.81% |
| 2009 | -1.92 | -84.96% |
| 2008 | -12.76 | -137.01% |
| 2007 | 34.47 | -53.31% |
| 2006 | 73.81 | 81.19% |
| 2005 | 40.74 | 28.34% |
| 2004 | 31.74 | -65.78% |
| 2003 | 92.76 | -90.85% |
| 2002 | 1.01K | -27,142.68% |
| 2001 | -3.75 | -38.76% |
| 2000 | -6.12 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 47.48 | 56.80% |
US
|
|
| 27.43 | -9.43% |
FR
|
|
| - | - |
JP
|
|
| 56.89 | 87.88% |
US
|
|
| - | - |
CH
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.